Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days before the first dose of study intervention

Has a known additional malignancy that is progressing or requires active treatment within the past 2 years

Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

Has ocular or mucosal melanoma

Has an active autoimmune disease that has required systemic treatment in the past 2 years

Has an active infection requiring systemic therapy

Has known history of human immunodeficiency virus (HIV)

Has history of Hepatitis B or known Hepatitis C virus infection

Has a history of (noninfectious) pneumonitis

Has a history of active tuberculosis (TB)

Has received prior systemic anticancer therapy within 4 weeks prior to randomization

Has received prior radiotherapy within 2 weeks of first dose of study intervention

Has had major surgery \<3 weeks prior to first dose of study intervention

Has received a live vaccine within 30 days before the first dose of study intervention

Has participated in a study of an investigational agent within 4 weeks prior to the first dose of study intervention

Has had an allogeneic tissue/solid organ transplant

Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study

* Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula

* Has radiographic evidence of encasement of invasion of a major blood vessel, or of intratumoral cavitation

* Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study intervention

* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention

* Has urine protein ≥1 g/24-hour.

* Has presence of gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib

What this study is about